Hio Chung Kang, Ph.D.
- Assistant Research Biologist
Contact Information
2340 Sutter St, Room N261
San Francisco, CA 94143-1724
(415) 502-0555
[email protected]
Education
College of Science, Sookmyung Women's University, Korea, B.S., Biology, 1999
College of Medicine, Seoul National University, Korea, M.S., Tumor Biology, 2003
College of Medicine, Seoul National University, Korea, Ph.D., Tumor Biology, 2005
Postdoctoral Training
- Staff Scientist, National Cancer Center Research Institute, Korea, 2005-2007
- Postdoctoral fellow, Department of Pediatrics, University of California, San Francisco (UCSF), 2007-2008
- Postdoctoral fellow, UCSF Cancer Center, 2008-2010
- Associate Specialist, UCSF Cancer Center, 2011-2013
Biography
Dr. Hio Chung Kang is an Assistant Research Biologist in Thoracic Oncology Laboratory at the UCSF Helen Diller Family Comprehensive Cancer Center which she joined in 2013.
Dr. Kang graduated from Sookmyung Women's University in Korea with a B.S. in Biology. She then received her M.S. and Ph.D. in Seoul National University, Korea in Tumor Biology. After she completed her doctoral work, Dr. Kang received an appointment as a staff scientist at the National Cancer Center Research Institute, Korea. Thereafter, in 2007, she came to UCSF, initially as a postdoctoral fellow, and now in the role of an Associate Specialist.
Dr. Kang has been an author on approximately forty peer-reviewed research papers related to her own research projects and in conjunction with collaborative researchers. In the past, she served as a principal investigator in the Genomic Core laboratory in National Cancer Center Research Institute.
At UCSF, Dr. Kang has played a pivotal role in coordinating genomic analysis - gene expression analysis, genome-wide genotyping, next-generation sequencing, through her management of a mouse tissue bank constructed from a number of mouse tumor models.
Research Overview
Dr. Kang's research interest focuses on the understanding of cancer as a genetic disease, the identification of tumor susceptibility genes and the genomic signature of cancer cells, all with the goal of discovering new therapeutic targets and drug resistance genes. Dr. Kang has explored genetic alterations in various inherited cancer syndromes as well as mutations in sporadic solid tumors, genome-wide expression profiling of acquired drug-resistant cancer cells, polymorphic variants associated with cancer risk, and chemically induced carcinogenesis in genetically engineered mouse models.